Gilead Sciences (GILD) on Monday said it would acquire privately held Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases. The agreement includes $1.675 ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

When a virus enters the lungs, the immune system has to react fast. The lung maintains its own community of immune cells ...

Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...